Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma. Issue 22 (1st October 2021)
- Record Type:
- Journal Article
- Title:
- Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma. Issue 22 (1st October 2021)
- Main Title:
- Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
- Authors:
- Zhang, Huan
Shan, Guangyao
Cai, Benjie
Bi, Guoshu
Chen, Zhencong
Liang, Jiaqi
Besskaya, Valeria
Zheng, Yuansheng
Guo, Weigang
Wang, Lin
Xu, Songtao
Zhan, Cheng - Abstract:
- Abstract: Background: The prognostic significance of ALK rearrangement is still contradictory. Here, we aimed to investigate the clinical characteristics and outcomes of lung adenocarcinoma patients with ALK rearrangement, and analyze whether these patients benefited from targeted therapy. Methods: This was a retrospective cohort study of 80 ALK‐rearranged lung adenocarcinoma patients who had undergone radical surgery and another 3031 ALK mutation‐negative patients were retrospectively reviewed for inclusion in this case‐controlled analyses. Overall survival (OS) was evaluated using the Kaplan‐–Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) by the Cox proportional hazards regression identified risk factors that predicted OS. Results: Compared to ALK‐negative patients, the ALK rearranged patients were younger, with more non‐smokers, more females, a larger primary tumor was demonstrated, and were a higher pathological stage. In particular, the risk of lymph node metastasis was higher. For patients with surgically‐resected tumors, the prognosis was better for ALK rearranged patients (HR = 0.503; 95% CI: 0.259–0.974, p = 0.041). In addition, for stage II–III patients, targeted therapy was an independent prognostic factor of better OS (HR = 0.159; 95% CI: 0.032–0.801, p = 0.026). Conclusions: ALK rearranged lung adenocarcinoma patients who have undergone radical surgery have distinct clinical features. Patients with ALK rearrangement may have aAbstract: Background: The prognostic significance of ALK rearrangement is still contradictory. Here, we aimed to investigate the clinical characteristics and outcomes of lung adenocarcinoma patients with ALK rearrangement, and analyze whether these patients benefited from targeted therapy. Methods: This was a retrospective cohort study of 80 ALK‐rearranged lung adenocarcinoma patients who had undergone radical surgery and another 3031 ALK mutation‐negative patients were retrospectively reviewed for inclusion in this case‐controlled analyses. Overall survival (OS) was evaluated using the Kaplan‐–Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) by the Cox proportional hazards regression identified risk factors that predicted OS. Results: Compared to ALK‐negative patients, the ALK rearranged patients were younger, with more non‐smokers, more females, a larger primary tumor was demonstrated, and were a higher pathological stage. In particular, the risk of lymph node metastasis was higher. For patients with surgically‐resected tumors, the prognosis was better for ALK rearranged patients (HR = 0.503; 95% CI: 0.259–0.974, p = 0.041). In addition, for stage II–III patients, targeted therapy was an independent prognostic factor of better OS (HR = 0.159; 95% CI: 0.032–0.801, p = 0.026). Conclusions: ALK rearranged lung adenocarcinoma patients who have undergone radical surgery have distinct clinical features. Patients with ALK rearrangement may have a favorable prognosis, and stage II–III patients may benefit from targeted treatment. Abstract : The article compared 80 ALK+ and 3031 ALK‐ lung adenocarcinoma patients after surgery, explored the clinicopathological characteristics and prognostic features of ALK+ lung adenocarcinoma patients, and analyzed the impact of targeted drugs on the survival of ALK+ lung adenocarcinoma patients after surgery. … (more)
- Is Part Of:
- Thoracic cancer. Volume 12:Issue 22(2021)
- Journal:
- Thoracic cancer
- Issue:
- Volume 12:Issue 22(2021)
- Issue Display:
- Volume 12, Issue 22 (2021)
- Year:
- 2021
- Volume:
- 12
- Issue:
- 22
- Issue Sort Value:
- 2021-0012-0022-0000
- Page Start:
- 3011
- Page End:
- 3018
- Publication Date:
- 2021-10-01
- Subjects:
- ALK inhibitors -- anaplastic lymphoma kinase (ALK) -- clinical feature -- lung adenocarcinoma -- prognosis
Chest -- Cancer -- Periodicals
Chest -- Cancer -- Treatment -- Periodicals
Chest -- Surgery -- Periodicals
616.99494005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291759-7714;jsessionid=9202029487E02D838DF722140677202D.d04t01 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1759-7714 ↗
http://onlinelibrary.wiley.com/ ↗
http://www.wiley.com/bw/journal.asp?ref=1759-7706&site=1 ↗ - DOI:
- 10.1111/1759-7714.14170 ↗
- Languages:
- English
- ISSNs:
- 1759-7706
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8820.242500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 19822.xml